Published in Proc Natl Acad Sci U S A on January 27, 2003
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A (2003) 8.20
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science (2009) 5.23
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A (2004) 4.27
PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res (2008) 3.92
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A (2005) 3.15
Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature (2005) 2.67
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet (2004) 2.53
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42
Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J Cell Biol (2003) 2.12
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation (2013) 2.03
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A (2008) 1.86
Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation (2014) 1.83
A cut above the rest: the regulatory function of plant proteases. Planta (2004) 1.69
Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem (2009) 1.67
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res (2010) 1.64
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis (2008) 1.56
Genetics: a gene of rare effect. Nature (2013) 1.54
The PCSK9 decade. J Lipid Res (2012) 1.50
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem (2009) 1.49
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J (2007) 1.48
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) (2010) 1.43
Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res (2010) 1.36
Hes6 promotes cortical neurogenesis and inhibits Hes1 transcription repression activity by multiple mechanisms. Mol Cell Biol (2003) 1.36
The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. Mol Biol Cell (2005) 1.30
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A (2007) 1.29
Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem (2013) 1.29
The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem (2013) 1.27
Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem (2015) 1.24
Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta (2009) 1.23
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther (2011) 1.23
Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse. Mol Cell Biol (2006) 1.23
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One (2010) 1.19
Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res (2012) 1.18
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res (2008) 1.18
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One (2013) 1.18
In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem (2010) 1.18
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep (2008) 1.17
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Res (2010) 1.17
Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry (2008) 1.16
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest (2012) 1.14
Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Curr Opin Struct Biol (2007) 1.13
Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements. J Lipid Res (2009) 1.11
Insights from bacterial subtilases into the mechanisms of intramolecular chaperone-mediated activation of furin. Methods Mol Biol (2011) 1.10
Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem (2010) 1.04
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One (2012) 1.04
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis (2011) 1.03
PCSK9 function and physiology. J Lipid Res (2008) 1.03
Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia (2012) 1.02
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors. J Lipid Res (2011) 1.00
Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem (2012) 1.00
The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis (2011) 0.98
Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r-like protein. Proc Natl Acad Sci U S A (2004) 0.98
Identification of novel genes and pathways regulating SREBP transcriptional activity. PLoS One (2009) 0.97
The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem (2012) 0.96
Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem (2015) 0.95
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther (2013) 0.94
Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells. J Lipid Res (2010) 0.93
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res (2011) 0.93
PCSK9 function and physiology. J Lipid Res (2008) 0.92
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol (2007) 0.92
Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations. Med Sci Monit (2014) 0.91
Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth. Neoplasia (2012) 0.91
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol (2014) 0.91
Proprotein convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor. J Biol Chem (2011) 0.91
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res (2010) 0.91
The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J (2014) 0.91
Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem (2013) 0.90
Isolation and characterization of the circulating truncated form of PCSK9. J Lipid Res (2014) 0.90
Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem (2011) 0.90
Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis (2014) 0.89
Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice. Proc Natl Acad Sci U S A (2013) 0.89
Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev (2008) 0.89
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc Disord (2014) 0.88
Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. J Lipid Res (2010) 0.88
Molecular population genetics of PCSK9: a signature of recent positive selection. Pharmacogenet Genomics (2008) 0.88
Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure. Oman Med J (2013) 0.88
PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment. J Lipid Res (2013) 0.88
Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis (2013) 0.87
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem (2012) 0.87
Propeptides are sufficient to regulate organelle-specific pH-dependent activation of furin and proprotein convertase 1/3. J Mol Biol (2012) 0.87
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (Lond) (2013) 0.87
Genetics of coronary artery disease: an update. Methodist Debakey Cardiovasc J (2014) 0.87
Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-A(y) mice. Lipids Health Dis (2012) 0.87
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One (2014) 0.86
Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem (2012) 0.86
The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis. J Biol Chem (2014) 0.86
The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. Arterioscler Thromb Vasc Biol (2013) 0.86
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res (2014) 0.86
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol (2015) 0.85
Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications. Int J Cell Biol (2013) 0.85
ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell (2000) 9.13
Liver regeneration. J Hepatol (2000) 5.22
Subtilases: the superfamily of subtilisin-like serine proteases. Protein Sci (1997) 4.86
Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res (1999) 3.79
The proprotein convertases. Curr Opin Chem Biol (1998) 3.79
Post-translational proteolysis in polypeptide hormone biosynthesis. Annu Rev Physiol (1982) 3.43
Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. Mol Cell (1998) 2.90
Distinct roles for bFGF and NT-3 in the regulation of cortical neurogenesis. Neuron (1995) 2.90
Proteolytic processing in the secretory pathway. J Biol Chem (1999) 2.75
The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. Biochimie (1994) 2.64
Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A (2000) 2.54
Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci U S A (1999) 2.37
Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem (2001) 2.11
cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc Natl Acad Sci U S A (1996) 2.10
Molecular mechanisms underlying cell fate specification in the developing telencephalon. Curr Opin Neurobiol (2002) 1.98
Multipotent neural stem cells reside into the rostral extension and olfactory bulb of adult rodents. J Neurosci (2002) 1.81
Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol (2002) 1.68
Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J Neurochem (2000) 1.48
Endoproteolytic cleavage of its propeptide is a prerequisite for efficient transport of furin out of the endoplasmic reticulum. J Biol Chem (1995) 1.43
Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J Biol Chem (2001) 1.42
Biosynthesis and enzymatic characterization of human SKI-1/S1P and the processing of its inhibitory prosegment. J Biol Chem (2000) 1.42
The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J Biol Chem (1999) 1.37
Liver regeneration after hepatectomy. Hepatogastroenterology (2001) 1.35
A critical temporal requirement for the retinoblastoma protein family during neuronal determination. J Cell Biol (1998) 1.34
A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet (1999) 1.34
A C-terminal domain conserved in precursor processing proteases is required for intramolecular N-terminal maturation of pro-Kex2 protease. EMBO J (1994) 1.33
Widespread expression of netrin-1 by neurons and oligodendrocytes in the adult mammalian spinal cord. J Neurosci (2001) 1.24
Role for Hes1-induced phosphorylation in Groucho-mediated transcriptional repression. Mol Cell Biol (2002) 1.24
Tubulogenesis in the developing mammalian kidney. Trends Cell Biol (2002) 1.22
Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein). J Clin Pathol (1994) 1.18
Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins. J Biol Chem (1999) 1.16
In vitro characterization of the novel proprotein convertase PC7. J Biol Chem (1997) 1.14
Evidence that helix-loop-helix proteins collaborate with retinoblastoma tumor suppressor protein to regulate cortical neurogenesis. J Neurosci (2000) 1.11
Folding pathway mediated by an intramolecular chaperone: propeptide release modulates activation precision of pro-subtilisin. J Biol Chem (2001) 1.11
A rapid fluorometric assay for the proteolytic activity of SKI-1/S1P based on the surface glycoprotein of the hemorrhagic fever Lassa virus. FEBS Lett (2002) 1.08
Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol (2000) 1.04
A model for the structure of the P domains in the subtilisin-like prohormone convertases. Proc Natl Acad Sci U S A (1998) 0.98
The metalloendopeptidase nardilysin (NRDc) is potently inhibited by heparin-binding epidermal growth factor-like growth factor (HB-EGF). Biochem J (2002) 0.97
Binding of BiP to the processing enzyme lymphoma proprotein convertase prevents aggregation, but slows down maturation. J Biol Chem (2000) 0.96
The RGD motif and the C-terminal segment of proprotein convertase 1 are critical for its cellular trafficking but not for its intracellular binding to integrin alpha5beta1. J Biol Chem (1999) 0.94
Primary structure and morphine-like activity of human beta-endorphin. Can J Biochem (1977) 0.94
Biosynthetic processing and quaternary interactions of proprotein convertase SPC4 (PACE4). FEBS Lett (1998) 0.94
Liver regrowth and apolipoprotein B secretion by rat hepatocytes following partial hepatectomy. Metabolism (1994) 0.92
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
The timing of cortical neurogenesis is encoded within lineages of individual progenitor cells. Nat Neurosci (2006) 4.49
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem (2004) 4.37
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol (2004) 4.08
Automated design of ligands to polypharmacological profiles. Nature (2012) 3.54
The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov (2012) 3.18
Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci (2003) 2.67
The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol (2008) 2.38
Implication of the proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin. Hepatology (2013) 2.24
Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res (2006) 2.17
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic (2007) 2.09
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology (2008) 2.07
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem (2007) 1.84
Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem (2011) 1.79
The 'Marx' of Groucho on development and disease. Trends Cell Biol (2007) 1.73
A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res (2010) 1.64
The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest (2003) 1.51
Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J Mol Med (Berl) (2011) 1.51
Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J Virol (2003) 1.50
The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis (2011) 1.50
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem (2009) 1.49
Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem (2002) 1.47
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J (2005) 1.43
Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J Biol Chem (2001) 1.42
The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med (Berl) (2007) 1.40
Hes6 promotes cortical neurogenesis and inhibits Hes1 transcription repression activity by multiple mechanisms. Mol Cell Biol (2003) 1.36
MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. Oncogene (2002) 1.34
VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5. Genes Dev (2008) 1.32
Role for Runx1 in the proliferation and neuronal differentiation of selected progenitor cells in the mammalian nervous system. J Neurosci (2005) 1.31
The proline-rich homeodomain protein recruits members of the Groucho/Transducin-like enhancer of split protein family to co-repress transcription in hematopoietic cells. J Biol Chem (2004) 1.28
Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest (2008) 1.27
Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation (2012) 1.26
Role for Hes1-induced phosphorylation in Groucho-mediated transcriptional repression. Mol Cell Biol (2002) 1.24
Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol (2011) 1.24
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
TCF and Groucho-related genes influence pituitary growth and development. Mol Endocrinol (2003) 1.24
Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies. Cancer Res (2008) 1.23
Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse. Mol Cell Biol (2006) 1.23
In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate. Proc Natl Acad Sci U S A (2008) 1.20
Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase. J Biol Chem (2005) 1.20
The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem (2006) 1.20
Groucho suppresses Pax2 transactivation by inhibition of JNK-mediated phosphorylation. EMBO J (2003) 1.18
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One (2013) 1.18
In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem (2010) 1.18
Inhibitors of proprotein convertases. J Mol Med (Berl) (2005) 1.17
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Res (2010) 1.17
Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein. J Biol Chem (2008) 1.14
A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction. J Clin Invest (2003) 1.12
Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol (2009) 1.12
Crystal structure of the C-terminal WD40 repeat domain of the human Groucho/TLE1 transcriptional corepressor. Structure (2002) 1.12
Phosphorylation of serine 239 of Groucho/TLE1 by protein kinase CK2 is important for inhibition of neuronal differentiation. Mol Cell Biol (2004) 1.11
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett (2009) 1.10
Processing of alpha4 integrin by the proprotein convertases: histidine at position P6 regulates cleavage. Biochem J (2003) 1.10
Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem (2006) 1.09
Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus. Biochem Biophys Res Commun (2005) 1.08
Inhibition of cortical neuron differentiation by Groucho/TLE1 requires interaction with WRPW, but not Eh1, repressor peptides. J Biol Chem (2008) 1.05
Hes6 inhibits astrocyte differentiation and promotes neurogenesis through different mechanisms. J Neurosci (2006) 1.04
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One (2012) 1.04
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology (2009) 1.03
Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia (2012) 1.02
Beta-amyloid protein converting enzyme 1 and brain-specific type II membrane protein BRI3: binding partners processed by furin. J Neurochem (2005) 1.02
Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas. Neoplasia (2008) 1.01
Loss of endothelial furin leads to cardiac malformation and early postnatal death. Mol Cell Biol (2012) 1.00
Regulation of postnatal forebrain amoeboid microglial cell proliferation and development by the transcription factor Runx1. J Neurosci (2012) 1.00
Role of pro-IGF-II processing by proprotein convertase 4 in human placental development. Proc Natl Acad Sci U S A (2005) 0.99
Furin is the major processing enzyme of the cardiac-specific growth factor bone morphogenetic protein 10. J Biol Chem (2011) 0.99
Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases. Oncogene (2005) 0.99
The proprotein convertase SKI-1/S1P: alternate translation and subcellular localization. J Biol Chem (2007) 0.98
The proprotein convertase PC7: unique zymogen activation and trafficking pathways. J Biol Chem (2010) 0.98
Structure-function analysis of the prosegment of the proprotein convertase PC5A. J Biol Chem (2002) 0.97
Cofactor-activated phosphorylation is required for inhibition of cortical neuron differentiation by Groucho/TLE1. PLoS One (2009) 0.97
The metalloendopeptidase nardilysin (NRDc) is potently inhibited by heparin-binding epidermal growth factor-like growth factor (HB-EGF). Biochem J (2002) 0.97
Antagonistic effects of Grg6 and Groucho/TLE on the transcription repression activity of brain factor 1/FoxG1 and cortical neuron differentiation. Mol Cell Biol (2005) 0.97
A role for cell cycle-regulated phosphorylation in Groucho-mediated transcriptional repression. J Biol Chem (2002) 0.96
Inhibition of cortical astrocyte differentiation by Hes6 requires amino- and carboxy-terminal motifs important for dimerization and phosphorylation. J Neurochem (2007) 0.94
PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res (2011) 0.93
Role for TGF-beta superfamily signaling in telencephalic GABAergic neuron development. J Neurodev Disord (2009) 0.93